Archive · 22 Dec 2025
Lupin Focuses on Complex Drugs for Growth
Lupin is a big medicine company that wants to keep growing.
They are focusing on making special kinds of medicines that are harder for others to copy, like complex generics and biosimilars.
This means they can charge more and make more money.
They also want to be more efficient and expand in important places like India and the US.
They are investing a lot of money in new factories and research.
The company's boss, Vinita Gupta, says they are doing well and plan to keep growing by making better medicines and using new technologies.
They also want to buy other companies to get into new areas, like eye medicines in Europe.
Overall, they are trying to become a company that is known for making new and innovative medicines.
Lupin is focusing on complex generics, biosimilars, and specialty products to sustain growth.
FY25 saw a 12.9% year-on-year sales increase to ₹221,921 crore, with EBITDA margins improving to 24.7%.
The company is investing $250 million over five years in a new inhalation manufacturing facility in Florida.
Lupin is building a global pipeline for biosimilars, with 70% of R&D budget allocated to high-barrier products.
The company plans to acquire VISUfarma in Europe to expand its presence in ophthalmology and specialty segments.
- Who
- Lupin, a pharmaceutical company, led by CEO Vinita Gupta
- What
- Lupin is focusing on complex generics, biosimilars, and specialty products to sustain growth
- When
- The strategy is part of their FY25 financial year and future plans
- Where
- Key markets include India and the US, with expansion in Europe through acquisitions
- Why
- To maintain growth, improve operational efficiency, and capture opportunities in high-barrier products
- Company
- Lupin
- CEO
- Vinita Gupta
- FY25 Sales Growth
- 12.9% year-on-year
- EBITDA Margins
- 24.7%
- US Market Rank
- Third-largest generic pharmaceutical company by prescription volume
- Investment in Florida
- $250 million over five years
- R&D Focus
- 70% allocated to high-barrier products
- Key Growth Areas
- Complex generics, biosimilars, specialty products